Literature DB >> 7838375

Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex.

P Dournaud1, P Cervera-Pierot, E Hirsch, F Javoy-Agid, C Kordon, Y Agid, J Epelbaum.   

Abstract

The level of expression of somatostatin messenger RNA-containing neurons in human brain was visualized and quantified by in situ hybridization with a 35S-labelled oligonucleotide complementary to amino acids 96-111 of the preprosomatostatin complementary DNA sequence. The analysis was carried out in the frontal and parahippocampal cortices and hippocampus of six age- and post mortem delay-matched Alzheimer's disease and control brains. By northern blot analysis, in frontal cortex samples, 18S rRNA degradation was identical in control and Alzheimer brains and somatostatin messenger RNAs migrated as a single band of 1 kb. By in situ hybridization, specificity was demonstrated by abolition of the signal using either an excess of unlabelled antisense probe or using a labelled sense probe. Somatostatin messenger RNA-containing neurons displayed a similar regional and subregional distribution in control subjects and patients with Alzheimer's disease, being more abundant in the frontal cortex, followed by the hippocampus and the parahippocampal cortex. An overall reduction of labelled cell density was observed in patients with Alzheimer's disease (frontal cortex gray matter:--41%; white matter:--66%; hippocampus:--44%; parahippocampal cortex white matter:--40%). Due to a great variation between brains, this decrease only reached significance in the parahippocampal cortex (-59%, P < 0.05). A significantly lower level of expression of somatostatin messenger RNA per somatostatinergic cell was observed in the hippocampus of Alzheimer's disease patients (-47%, P < 0.05), but not in frontal cortex gray (-17%) and white (-36%) matter and parahippocampal cortex gray (-42%) and white (-29%) matter. These data are in accordance with the distribution of somatostatin cells as visualized by immunohistochemistry in human brain. They indicate that the ability of cortical cells to express somatostatin messenger RNA is partially preserved in Alzheimer disease brains and that the decrease in the amount of somatostatin messenger RNA per cell is restricted to the hippocampal formation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7838375     DOI: 10.1016/0306-4522(94)90399-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Twenty-first century brain banking. Processing brains for research: the Columbia University methods.

Authors:  Jean Paul G Vonsattel; Maria Pilar Del Amaya; Christian E Keller
Journal:  Acta Neuropathol       Date:  2007-11-06       Impact factor: 17.088

2.  Age-associated changes in hippocampal-dependent cognition in Diversity Outbred mice.

Authors:  Ming Teng Koh; Amy M Spiegel; Michela Gallagher
Journal:  Hippocampus       Date:  2014-06-11       Impact factor: 3.899

3.  Neurochemical parameters in senile dementia of the Alzheimer type. A longitudinal study in four cases.

Authors:  M Strittmatter; G Hamann; H Cramer; C Reuner; F Kuntzmann; D Strubel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

4.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

5.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Neurochemical phenotype of cytoglobin-expressing neurons in the rat hippocampus.

Authors:  Christian Ansgar Hundahl; Jan Fahrenkrug; Jens Hannibal
Journal:  Biomed Rep       Date:  2014-06-16

Review 7.  Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

Authors:  Li-Chun Lin; Etienne Sibille
Journal:  Front Pharmacol       Date:  2013-09-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.